admin The makers of Ozempic have said that their weight loss drug Wegovy will be newly launched in Canada for their patients on Monday.
Novo Nordisk’s weekly injection has been given a thumbs up for weight loss which will significantly help the patients who are fighting obesity.
Wegovy can also be prescribed to patients who are extremely overweight and are suffering from medical conditions which include high blood pressure, Type 2 diabetes and even obstructive sleep apnea.
Dr. Sanjeev Sockalingam from Obesity Canada has claimed that obesity is a medical condition which cannot be ignored as it can be fatal and Wegovy is said to be an effective option for weight loss.
He says that it is for medical use and not cosmetic.
Wegovy has the same medication – semaglutide – as the diabetes drug named Ozempic but it has a significantly higher dose.
“(Wegovy) adds to the toolbox and the tool kit for all clinicians who are seeing many patients living with obesity,” said Sockalingam, who is the scientific director for Obesity Canada, an organisation which focuses on enhancing the lives of people who are suffering from obesity.
It is meant to be used in tandem with physical activity and nutrition, according to him.
The news of Wegovy being launched comes as its parent company, Novo Nordisk, raised its 2024 outlook on Thursday and reported better than expected first quarter profits.
Novo, today, is the most valuable company in Europe by market capitalisation, which is worth more than US $576.44 billion before Thursday’s earnings on the back of Wegovy’s popularity. The company’s shares have gone up to 260 percent since Wegovy’s launch in the United States in the month of June 2021.
Health Canada has approved the drug, Wegocy in November 2021 relying on the studies that “demonstrated a statistically significantly greater amount of weight loss in semaglutide treated (patients) as compared to placebo treated subjects,” according to the federal government’s website.
Magazine
